SBIR Phase I: Innovations in Nanoscale Manufacturing: Assembly of Nanomaterial Components via Electrostatic Forces and Production of Composites for Bio-Medical Implants.

SBIR 第一阶段：纳米制造的创新：通过静电力组装纳米材料组件以及生产生物医学植入物复合材料。

• 批准号: 0944440
• 负责人: Joseph Bringley
• 金额: --
• 依托单位: TRANSPARENT MATERIALS, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0944440&HistoricalAwards=false
• 关键词: SBIR; Phase; Innovations; Nanoscale; Manufacturing

This Small Business Innovation Research Phase I project seeks to develop nanomanufacturing methods for producing metal-oxide composites for biomedical implants. Homogeneous, mixed metal-oxide composites are extremely difficult to prepare by existing processes, and although of great utility, mixed-oxides have found limited applications in markets outside of biomedicine due to cost constraints. We have obtained preliminary data demonstrating a new, highly-efficient and low-cost approach to the manufacture of these materials which uses precise flow and mixing control to assemble the individual components of the mixed-oxides at the nanoscale. The process utilizes inexpensive nanomaterial components (e.g., colloids) that are readily available. The process produces complex "core-shell" nanomaterials that are then further processed to produce a mixed-oxide with greatly increased functionality. We anticipate that these materials will exhibit the commercially important properties of radiopacity (aiding diagnostic capabilities) and bioactivity (for better implant integration).The broader impact/commercial potential of this project is to provide bio-medical implants that better integrate into the human body, speed the healing process, improve durability, extend the use-life and aid diagnosis. This will ultimately reduce the rate of revision surgery and improve patient outcomes. The process has many significant advantages over existing methods of manufacturing, including increased functionality, dramatically improved product yield (leading to lower cost), and significantly improved performance. This process provides a significant manufacturing cost advantage over existing materials and can be further leveraged to expand market opportunities into adjacent segments where cost constraints have limited the adoption of advanced composites.

这个小企业创新研究第一阶段项目旨在开发纳米制造方法，用于生产生物医学植入物的金属氧化物复合材料。均质、混合金属氧化物复合材料极难用现有的工艺制备，尽管具有很大的用途，但由于成本限制，混合氧化物在生物医药以外的市场上的应用有限。我们已经获得了初步数据，证明了一种新的、高效的、低成本的方法来制造这些材料，这种方法使用精确的流动和混合控制来组装纳米级混合氧化物的各个组成部分。该工艺利用易于获得的廉价纳米材料成分（例如，胶体）。这个过程产生复杂的“核-壳”纳米材料，然后进一步加工产生功能大大增强的混合氧化物。我们预计这些材料将表现出商业上重要的不透光性（有助于诊断能力）和生物活性（更好地植入物整合）。该项目更广泛的影响/商业潜力是提供更好地融入人体、加速愈合过程、提高耐久性、延长使用寿命和辅助诊断的生物医学植入物。这将最终降低翻修手术率，改善患者预后。与现有的制造方法相比，该工艺具有许多显著的优势，包括增强的功能、显著提高的产品产量（导致更低的成本）和显著提高的性能。与现有材料相比，该工艺具有显著的制造成本优势，可以进一步扩大市场机会，进入成本限制先进复合材料采用的邻近领域。